Cardiol Therapeutics Inc. (NASDAQ: CRDL)
$2.20
+0.0650 ( +3.05% ) 230.8K
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Market Data
Open
$2.20
Previous close
$2.13
Volume
230.8K
Market cap
$151.80M
Day range
$2.09 - $2.21
52 week range
$0.66 - $3.12
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 5 | Jun 27, 2024 |
6-k | Quarterly Reports | 3 | Jun 25, 2024 |
6-k | Quarterly Reports | 3 | Jun 13, 2024 |
6-k | Quarterly Reports | 10 | May 28, 2024 |
6-k | Quarterly Reports | 7 | May 14, 2024 |
6-k | Quarterly Reports | 3 | May 14, 2024 |
6-k | Quarterly Reports | 3 | Apr 26, 2024 |
6-k | Quarterly Reports | 3 | Apr 02, 2024 |
20-f | Annual reports | 116 | Apr 01, 2024 |
6-k | Quarterly Reports | 3 | Feb 26, 2024 |